静脉治疗用于去势抵抗性前列腺癌：毒性和不良反应。
Intravenous therapies for castration-resistant prostate cancer: toxicities and adverse events.
机构信息
Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
出版信息
Urol Oncol. 2012 Jul-Aug;30(4 Suppl):S15-9. doi: 10.1016/j.urolonc.2011.09.003. Epub 2011 Oct 19.
Abstract
Prostate cancer (CaP) continues to be a significant burden on men's health. While significant advances have been made in the diagnosis and treatment of localized disease, androgen deprivation therapy remains the treatment of choice for advanced and metastatic disease. However, once a man progresses on androgen deprivation, therapies targeting castration-resistant CaP have been extremely limited until quite recently. Urologic oncologists who wish to play an active role in the treatment of men with CaP from diagnosis through end-of-life care should be familiar with administration of and toxicities associated with chemotherapeutic agents. This review is directed at urologists and urologic oncologists and will discuss many of the FDA-approved intravenous agents currently available for castration-resistant CaP with a specific focus on the side-effects associated with these regimens.
摘要
前列腺癌（CaP）仍然是男性健康的重大负担。尽管在局部疾病的诊断和治疗方面取得了重大进展，但雄激素剥夺疗法仍然是晚期和转移性疾病的治疗选择。然而，一旦男性进展为雄激素剥夺，针对去势抵抗性 CaP 的治疗方法一直非常有限，直到最近才有所改善。希望在从诊断到临终关怀的整个阶段积极参与 CaP 男性治疗的泌尿外科医生应该熟悉化疗药物的使用和相关毒性。本综述面向泌尿科医生和泌尿科肿瘤学家，将讨论目前许多获得 FDA 批准的用于去势抵抗性 CaP 的静脉内药物，并特别关注这些方案相关的副作用。
相似文献
1
Intravenous therapies for castration-resistant prostate cancer: toxicities and adverse events.静脉治疗用于去势抵抗性前列腺癌：毒性和不良反应。
Urol Oncol. 2012 Jul-Aug;30(4 Suppl):S15-9. doi: 10.1016/j.urolonc.2011.09.003. Epub 2011 Oct 19.
2
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial.多西他赛、唑来膦酸或两者联合添加至前列腺癌一线长期激素治疗（STAMPEDE）：一项适应性、多组、多阶段、平台随机对照试验的生存结果
Lancet. 2016 Mar 19;387(10024):1163-77. doi: 10.1016/S0140-6736(15)01037-5. Epub 2015 Dec 21.
3
Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies.治疗转移性去势抵抗性前列腺癌患者：现有疗法的全面综述
J Urol. 2015 Dec;194(6):1537-47. doi: 10.1016/j.juro.2015.06.106. Epub 2015 Jul 18.
4
Optimizing the use of docetaxel in men with castration-resistant metastatic prostate cancer.优化多西他赛在去势抵抗性转移性前列腺癌男性患者中的应用。
Prostate Cancer Prostatic Dis. 2010 Jun;13(2):108-16. doi: 10.1038/pcan.2009.62. Epub 2010 Jan 12.
5
Castration-resistant prostate cancer: systemic therapy in 2012.去势抵抗性前列腺癌：2012 年的系统治疗。
Clinics (Sao Paulo). 2012;67(4):389-94. doi: 10.6061/clinics/2012(04)13.
6
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.多西他赛治疗后进展的转移性去势抵抗性前列腺癌患者中，泼尼松联合卡巴他赛或米托蒽醌治疗的随机开放标签试验。
Lancet. 2010 Oct 2;376(9747):1147-54. doi: 10.1016/S0140-6736(10)61389-X.
7
[Strategy in advanced castration-resistant prostate cancer].[晚期去势抵抗性前列腺癌的治疗策略]
Bull Cancer. 2012 Jul;99 Suppl 1:S37-45. doi: 10.1684/bdc.2012.1562.
8
Quality of life with advanced metastatic prostate cancer.晚期转移性前列腺癌患者的生活质量。
Urol Clin North Am. 2012 Nov;39(4):505-15. doi: 10.1016/j.ucl.2012.07.007. Epub 2012 Aug 27.
9
Prevention of bone metastases in patients with high-risk nonmetastatic prostate cancer treated with zoledronic acid: efficacy and safety results of the Zometa European Study (ZEUS).唑来膦酸治疗高危非转移性前列腺癌患者的骨转移预防：唑来膦酸欧洲研究（ZEUS）的疗效和安全性结果。
Eur Urol. 2015 Mar;67(3):482-91. doi: 10.1016/j.eururo.2014.02.014. Epub 2014 Feb 20.
10
Cabazitaxel: a new drug for metastatic prostate cancer.卡巴他赛：一种用于转移性前列腺癌的新药。
Asian J Androl. 2011 Mar;13(2):185-6. doi: 10.1038/aja.2010.161. Epub 2010 Dec 13.
引用本文的文献
1
Overcoming drug resistance in castrate-resistant prostate cancer: current mechanisms and emerging therapeutic approaches.克服去势抵抗性前列腺癌中的耐药性：当前机制与新兴治疗方法
Cancer Drug Resist. 2025 Feb 19;8:9. doi: 10.20517/cdr.2024.173. eCollection 2025.
2
Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial.Lu-PSMA-617 与改变雄激素受体通路抑制剂治疗用于未经紫杉烷治疗的进展性转移性去势抵抗性前列腺癌患者（PSMAfore）：一项 3 期随机对照试验。
Lancet. 2024 Sep 28;404(10459):1227-1239. doi: 10.1016/S0140-6736(24)01653-2. Epub 2024 Sep 15.
3
A systemic review of taxanes and their side effects in metastatic breast cancer.紫杉烷类药物及其在转移性乳腺癌中的副作用的系统评价。
Front Oncol. 2022 Oct 11;12:940239. doi: 10.3389/fonc.2022.940239. eCollection 2022.
4
Non-Canonical Cannabinoid Receptors with Distinct Binding and Signaling Properties in Prostate and Other Cancer Cell Types Mediate Cell Death.非典型大麻素受体在前列腺和其他癌细胞类型中具有不同的结合和信号转导特性，介导细胞死亡。
Int J Mol Sci. 2022 Mar 11;23(6):3049. doi: 10.3390/ijms23063049.
5
Docetaxel and Doxorubicin Codelivery by Nanocarriers for Synergistic Treatment of Prostate Cancer.纳米载体共递送多西他赛和阿霉素用于前列腺癌的协同治疗
Front Pharmacol. 2019 Dec 18;10:1436. doi: 10.3389/fphar.2019.01436. eCollection 2019.
6
Cabazitaxel-loaded human serum albumin nanoparticles as a therapeutic agent against prostate cancer.载卡巴他赛的人血清白蛋白纳米粒作为一种抗前列腺癌的治疗剂。
Int J Nanomedicine. 2016 Jul 26;11:3451-9. doi: 10.2147/IJN.S105420. eCollection 2016.
7
Prevention and management of depression and suicidal behavior in men with prostate cancer.前列腺癌男性患者抑郁和自杀行为的预防与管理
Front Public Health. 2015 Feb 19;3:28. doi: 10.3389/fpubh.2015.00028. eCollection 2015.
8
Synergistic simvastatin and metformin combination chemotherapy for osseous metastatic castration-resistant prostate cancer.辛伐他汀与二甲双胍联合化疗对骨转移性去势抵抗性前列腺癌的协同作用
Mol Cancer Ther. 2014 Oct;13(10):2288-302. doi: 10.1158/1535-7163.MCT-14-0451. Epub 2014 Aug 13.
9
Presentation and management of docetaxel-related adverse effects in patients with breast cancer.乳腺癌患者多西他赛相关不良反应的表现及管理
Cancer Manag Res. 2014 May 27;6:253-9. doi: 10.2147/CMAR.S40601. eCollection 2014.
10
Androgen synthesis inhibitors in the treatment of castration-resistant prostate cancer.雄激素合成抑制剂在去势抵抗性前列腺癌治疗中的应用。
Asian J Androl. 2014 May-Jun;16(3):387-400. doi: 10.4103/1008-682X.129133.
本文引用的文献
1
The changing therapeutic landscape of castration-resistant prostate cancer.去势抵抗性前列腺癌的治疗格局变化。
Nat Rev Clin Oncol. 2011 Aug 9;8(10):597-610. doi: 10.1038/nrclinonc.2011.117.
2
EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.EAU 前列腺癌指南。第二部分：晚期、复发性和去势抵抗性前列腺癌的治疗。
Eur Urol. 2011 Apr;59(4):572-83. doi: 10.1016/j.eururo.2011.01.025. Epub 2011 Jan 25.
3
Novel agents and new therapeutics in castration-resistant prostate cancer.新型药物在去势抵抗性前列腺癌中的应用
Curr Opin Oncol. 2011 May;23(3):290-6. doi: 10.1097/CCO.0b013e3283449400.
4
Global cancer statistics.全球癌症统计数据。
CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90. doi: 10.3322/caac.20107. Epub 2011 Feb 4.
5
Guidelines for the management of castrate-resistant prostate cancer.去势抵抗性前列腺癌管理指南
Can Urol Assoc J. 2010 Dec;4(6):380-4. doi: 10.5489/cuaj.10167.
6
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.多西他赛治疗后进展的转移性去势抵抗性前列腺癌患者中，泼尼松联合卡巴他赛或米托蒽醌治疗的随机开放标签试验。
Lancet. 2010 Oct 2;376(9747):1147-54. doi: 10.1016/S0140-6736(10)61389-X.
7
Treatment and prevention of bone complications from prostate cancer.前列腺癌相关骨并发症的治疗与预防。
Bone. 2011 Jan;48(1):88-95. doi: 10.1016/j.bone.2010.05.038. Epub 2010 May 31.
8
Cancer statistics, 2010.癌症统计数据，2010 年。
CA Cancer J Clin. 2010 Sep-Oct;60(5):277-300. doi: 10.3322/caac.20073. Epub 2010 Jul 7.
9
Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors.新型紫杉烷类化合物XRP6258（RPR 116258A）在晚期实体瘤患者中每3周进行1小时静脉滴注给药的I期药代动力学研究。
Clin Cancer Res. 2009 Jan 15;15(2):723-30. doi: 10.1158/1078-0432.CCR-08-0596.
10
Androgen deprivation therapy for advanced prostate cancer: why does it fail and can its effects be prolonged?晚期前列腺癌的雄激素剥夺治疗：为何会失败，其疗效能否延长？
Can J Urol. 2008 Dec;15(6):4381-7.
Zotero 插件